Quince Therapeutics, Inc.
About Quince Therapeutics, Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$84.0M
- Total assets
- $93.5M
- Market cap
- $19.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $58.1M
- Operating income
- -$58.1M
- Income tax
- $3.2M
- Net income
- -$80.8M
- EPS (basic)
- $-1.68
- EPS (diluted)
- $-1.68
Balance sheet
- Total assets
- $93.5M
- Current assets
- $22.9M
- Total liabilities
- $129.2M
- Current liabilities
- $43.2M
- Shareholders’ equity
- -$35.7M
Cash flow
- Operating cash flow
- -$41.4M
- Investing cash flow
- $23.2M
- Financing cash flow
- $17.9M
- Net cash flow
- -$403.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $19.8M
- EPS (diluted)
- $-1.68
- Shares outstanding
- 19.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $84.0M.
- Trading 98% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Quince Therapeutics, Inc..
Write a review
News about Quince Therapeutics, Inc.
News & sentiment via Polygon.io
